Quotient Limited to Report Third Quarter 2021 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 19, 2021 (GLOBE NEWSWIRE) – Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021.
Quotient Limited Announces Departure of Chief Operating Officer
JERSEY, Channel Islands, 22 December 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020, Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer…
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed…
Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands, November 9, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company will participate in two upcoming virtual investor conferences.
Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
• FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received
• FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020
• European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark…
• FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020
• European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark…
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test
JERSEY, Channel Islands, 28 September 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that on September 25, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19…
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 20,294,117 ordinary shares at a price to the public…